Clinitech Laboratory

Mumbai, India Founded: 1990 • Age: 36 yrs Listed
Pathology lab services are operated through a chain in India.

About Clinitech Laboratory

Clinitech Laboratory is a publicly listed company based in Mumbai (India) founded in 1990. Pathology lab services are operated through a chain in India. Its chief executive, as recorded, is Jagdish Nayak. Its Indian entity Clinitech Laboratory Limited reported revenue of ₹9.68 Cr. Its focus areas include Clinical Laboratory Chains and Pathology. Similar companies include Dr Lal PathLabs, Redcliffe Labs and Sterling Accuris Diagnostics; 3 of its 3 listed similar companies have raised funding.

Company details

Clinitech Laboratory was founded in 1990 and functions as a chain of pathology labs based in Mumbai, India. Diagnostic services in pathology are delivered across multiple locations. Operations focus on medical testing and analysis for healthcare needs. Leadership is provided by CEO Jagdish Nayak. The company serves the healthcare sector within the Indian market.

  • Headquarters Mumbai, India
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website clinitechlab.com
  • Social X Facebook
  • Legal Name Clinitech Laboratory Limited
  • Date of Incorporation 19 Mar, 2010
  • Jurisdiction Navi Mumbai, Maharashtra, India
Operational Areas
Key Metrics
  • Market Cap
    ₹7.79 Cr

    CTLLAB · BSE

  • Share Price
    ₹32.05

    -6.15% today

  • Revenue
    ₹9.49 Cr

    FY 2025-26 · +15.3% YoY

  • EBITDA
    ₹1.00 Cr

    Margin 10.5%

  • Net Profit
    ₹0.43 Cr

    FY 2025-26 · +48.3% YoY

  • P/E (TTM)
    17.7x

    P/B 0.8x

  • ROE
    4.5%

    ROCE 6.9%

  • Debt / Equity
    0.03

    Interest cover 14.3x

Board of directors of Clinitech Laboratory Limited (Clinitech Laboratory)

Clinitech Laboratory Limited is the primary company behind Clinitech Laboratory. The boards of the 2 registered companies of Clinitech Laboratory currently have 7 directors; the longest-serving is Jyoti Jagdish Nayak, appointed in 2010. 6 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Jyoti Jagdish Nayak
DIN 02945625
Whole-time director19 Mar 201016 yrs 8 moClinitech Laboratory Limited
Jagdish Umakant Nayak
DIN 00646672
Designated Partner09 Jan 20215 yrs 10 moCtl Wellnz Llp, Clinitech Laboratory Limited
Ashutosh Jagdish Nayak
DIN 07553633
Designated Partner09 Jan 20215 yrs 10 moCtl Wellnz Llp, Clinitech Laboratory Limited
Kripananda Chidambaram
DIN 03030134
Partner09 Jan 20215 yrs 10 moCtl Wellnz Llp
Balu Laxman Kumbharkar
DIN 10180137
Director19 Jun 20233 yrs 5 moClinitech Laboratory Limited
Ravikant Moreshwar Mhatre
DIN 06362676
Director19 Jun 20233 yrs 5 moClinitech Laboratory Limited
Smita Arjun Patil
DIN 10147488
Director19 Jun 20233 yrs 5 moClinitech Laboratory Limited

People of Clinitech Laboratory

1 people are tracked at Clinitech Laboratory (1 in leadership).

NameRoleGroup
CEOLeadership
Premium access

Complete people profiles for Clinitech Laboratory

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Clinitech Laboratory

Clinitech Laboratory is a publicly listed company on the BSE with ticker symbol CTLLAB in India, operating in the Healthcare sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date01 Aug 2024
  • Listed onBSE: 544220
  • Listed entityClinitech Laboratory Limited
  • Exchange sectorHealthcare

Financials of Clinitech Laboratory

Exchange-reported figures of Clinitech Laboratory Limited, the listed company behind Clinitech Laboratory (BSE: CTLLAB).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹9.49 Cr
+15.3% YoY
EBITDA
₹1.00 Cr
+22.0% YoY
Profit After Tax
₹0.43 Cr
+48.3% YoY
Net Worth
₹9.25 Cr
+4.8% YoY
Total Assets
₹10.04 Cr
+11.2% YoY
Total Debt
₹0.54 Cr

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25
Income statement
Revenue9.498.23
Revenue growth+15.3%-
EBITDA1.000.82
EBITDA margin+10.5%+10.0%
Profit before tax0.610.54
Net profit0.430.29
Net profit margin+4.5%+3.5%
EPS (₹)1.831.73
Balance sheet
Total assets10.049.03
Net worth9.258.83
Total debt0.540.00
Cash & bank2.113.07
Net working capital6.235.65
Cash flow
Cash from operations(0.79)(0.88)
Cash from investing(0.68)(0.73)
Cash from financing0.513.98
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue9.488.236.406.356.384.55
Revenue growth+15.2%+28.6%+0.8%-0.5%+40.2%-
EBITDA1.000.821.001.361.060.83
EBITDA margin+10.6%+10.0%+15.6%+21.4%+16.6%+18.2%
Profit before tax0.610.540.510.860.690.54
Net profit0.430.290.370.610.500.37
Net profit margin+4.5%+3.5%+5.8%+9.6%+7.8%+8.1%
EPS (₹)1.851.732.214.093.426.04
Balance sheet
Total assets9.869.034.615.022.852.02
Net worth9.258.833.552.381.851.39
Total debt0.360.000.871.030.890.54
Cash & bank2.063.070.700.780.100.32
Net working capital6.315.651.700.950.550.92
Cash flow
Cash from operations(0.90)(0.88)(1.28)1.250.960.38
Cash from investing(0.44)(0.73)0.75(0.65)(1.47)0.54
Cash from financing0.333.980.450.090.29(0.88)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 21 Nov 2026
ParticularsFY 2025-26FY 2024-25
Revenue9.498.23
Revenue growth+15.3%-
Other income0.190.23
Total expenses8.497.41
Employee cost2.602.38
EBITDA1.000.82
EBITDA margin+10.5%+10.0%
Depreciation0.510.45
Interest0.070.06
Profit before tax0.610.54
Tax0.180.16
Net profit0.430.29
Net profit margin+4.5%+3.5%
EPS (₹)1.831.73
ParticularsFY 2025-26FY 2024-25
Equity & liabilities
Share capital2.282.28
Reserves & surplus6.976.55
Shareholders' funds (net worth)9.258.83
Minority interest0.000.00
Secured loans0.540.00
Unsecured loans0.000.00
Total debt0.540.00
Total liabilities10.049.03
Assets
Gross block5.905.33
Net block2.182.12
Capital work in progress1.251.01
Investments0.070.07
Inventories0.730.53
Sundry debtors1.851.54
Cash & bank balances2.113.07
Loans & advances2.682.32
Total current assets7.377.46
Total current liabilities1.141.81
Net working capital6.235.65
Total assets10.049.03
ParticularsFY 2025-26FY 2024-25
Opening cash3.070.70
Net cash from operating activities(0.79)(0.88)
Net cash from investing activities(0.68)(0.73)
Net cash from financing activities0.513.98
Net change in cash(0.96)2.37
Closing cash2.113.07
ParticularsFY 2025-26FY 2024-25
Growth
Sales growth+15.3%-
EBITDA growth+22.0%-
PBT growth+13.0%+9997.0%
Net income growth+48.3%-
Profitability & leverage
Net income margin+4.5%+4.6%
Return on capital employed+6.9%+6.0%
Return on net worth+4.5%+3.4%
Debt / equity0.030.00
Long-term debt / equity0.030.00
Interest cover14.2916.22
Efficiency & per share
Fixed asset turnover1.691.54
Inventory turnover15.0615.53
Debtors turnover5.605.34
EPS (₹)1.831.73
Dividend per share (₹)0.000.00
Book value per share (₹)40.5238.69
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue9.488.236.406.356.384.55
Revenue growth+15.2%+28.6%+0.8%-0.5%+40.2%-
Other income0.190.230.040.020.070.04
Total expenses8.487.415.404.995.323.72
Employee cost2.602.381.921.551.380.92
EBITDA1.000.821.001.361.060.83
EBITDA margin+10.6%+10.0%+15.6%+21.4%+16.6%+18.2%
Depreciation0.510.450.440.450.380.25
Interest0.070.060.090.070.060.08
Profit before tax0.610.540.510.860.690.54
Tax0.180.160.130.250.190.14
Net profit0.430.290.370.610.500.37
Net profit margin+4.5%+3.5%+5.8%+9.6%+7.8%+8.1%
EPS (₹)1.851.732.214.093.426.04
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital2.282.281.681.501.500.67
Reserves & surplus6.976.551.870.880.350.72
Shareholders' funds (net worth)9.258.833.552.381.851.39
Secured loans0.360.000.530.590.640.48
Unsecured loans0.000.000.340.440.250.06
Total debt0.360.000.871.030.890.54
Total liabilities9.869.034.615.022.852.02
Assets
Gross block5.905.334.473.653.522.45
Net block2.182.121.711.331.650.84
Capital work in progress0.991.010.940.560.410.08
Investments0.080.070.072.020.140.09
Inventories0.730.530.280.140.160.09
Sundry debtors1.851.540.600.490.360.56
Cash & bank balances2.063.070.700.780.100.32
Loans & advances2.722.321.120.550.760.66
Total current assets7.367.462.701.961.381.63
Total current liabilities1.051.811.001.010.830.71
Net working capital6.315.651.700.950.550.92
Total assets9.869.034.615.022.852.02
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash3.070.700.780.100.320.28
Net cash from operating activities(0.90)(0.88)(1.28)1.250.960.38
Net cash from investing activities(0.44)(0.73)0.75(0.65)(1.47)0.54
Net cash from financing activities0.333.980.450.090.29(0.88)
Net change in cash(1.01)2.37(0.08)0.68(0.22)0.04
Closing cash2.063.070.700.780.100.32
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth+15.2%+28.6%+0.8%-0.5%+40.2%-
EBITDA growth+22.0%-18.0%-26.5%+28.3%+27.7%-
PBT growth+13.0%+5.9%-40.7%+24.6%+27.8%+9997.0%
Net income growth+48.3%-21.6%-39.3%+22.0%+35.1%-
Revenue CAGR (3Y)+14.3%+8.9%+12.0%---
EBITDA CAGR (3Y)-9.7%-8.2%+6.4%---
Profitability & leverage
Net income margin+4.5%+4.6%+5.9%+9.6%+7.8%+8.8%
Return on capital employed+7.1%+7.9%+12.3%+23.6%+31.2%+30.7%
Return on net worth+4.7%+4.9%+12.5%+28.8%+31.5%+28.8%
Debt / equity0.020.070.320.450.440.38
Long-term debt / equity0.020.020.090.150.260.34
Interest cover14.2916.2216.077.698.8213.79
Efficiency & per share
Fixed asset turnover1.691.681.581.772.141.86
Inventory turnover15.0520.3230.4842.3351.0450.56
Debtors turnover5.597.6911.7414.9413.878.13
EPS (₹)1.851.732.214.093.426.04
Dividend per share (₹)0.000.000.000.000.000.00
Book value per share (₹)40.5438.6921.1215.8712.3220.86

Similar companies to Clinitech Laboratory

Clinitech Laboratory has 3 listed similar companies in our database, 3 of them funded. They include Dr Lal PathLabs, Redcliffe Labs and Sterling Accuris Diagnostics.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
lalpathlabs.com1949Gurugram, India$13.9M8,279
Chain of pathology and radiology labs
redcliffelabs.com2018Noida, India$116.42M2,104
Home-based diagnostic tests are booked via an online platform.
sterlingaccuris.com2015Ahmedabad, India$41.69M1,229
Pathology diagnostic services are offered via a chain of labs.
Premium access

Detailed similar companies of Clinitech Laboratory

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Diagnostics Laboratories

3 companies that operate in the same segment as Clinitech Laboratory (Diagnostics Laboratories) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Diagnostic testing centers for pathology and health screenings are operated.
1996Mumbai, Maharashtra, IndiaUSD 63.59 MUSD 90.17 M1,979
Chain of pathology and radiology labs
1949Gurugram, Haryana, IndiaUSD 13.9 MUSD 294.49 M5,310
Home-based diagnostic tests are booked via an online platform.
2018Noida, Uttar Pradesh, IndiaUSD 116.42 MUSD 52.45 M2,334
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Clinitech Laboratory

Premium access

Complete news archive for Clinitech Laboratory

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Clinitech Laboratory

Clinitech Laboratory was founded in 1990.

Clinitech Laboratory is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Jagdish Nayak is the CEO of Clinitech Laboratory, as recorded in our data.

The primary company behind Clinitech Laboratory, Clinitech Laboratory Limited, reported revenue of ₹9.68 Cr for FY 2026, up 15% year on year.

Clinitech Laboratory was founded in 1990 and functions as a chain of pathology labs based in Mumbai, India. Diagnostic services in pathology are delivered across multiple locations. Operations focus on medical testing and analysis for healthcare needs. Leadership is provided by CEO Jagdish Nayak. The company serves the healthcare sector within the Indian market.

Clinitech Laboratory's top competitors include Dr Lal PathLabs, Redcliffe Labs and Sterling Accuris Diagnostics.

Yes, Clinitech Laboratory is publicly traded on BSE under the ticker symbol CTLLAB.

Clinitech Laboratory is associated with 2 legal entities: Clinitech Laboratory Limited, Ctl Wellnz Llp.

The legal entities of Clinitech Laboratory currently have 9 directors, including Jagdish Umakant Nayak, Ashutosh Jagdish Nayak, Kripananda Chidambaram and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available